4.7 Article

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

期刊

PHARMACEUTICS
卷 14, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics14030505

关键词

breast cancer; nanomedicine; immune escape; cancer immunotherapy; cancer treatment

资金

  1. Instituto de Salud Carlos III [CP14/00197, CP19/00029, PI15/00336, PI19/01533]
  2. European Regional Development Fund (European Union)
  3. Ministerio de Ciencia e Innovacion [PID2020-115087GB-100, RTI2018.101309B-C22]
  4. Junta de Andalucia [B-CTS-410-UGR-20]
  5. Sistema Nacional de Garantia Juvenil (Fondo Social Europeo)
  6. Fundacion Cientifica Asociacion Espanola Contra el Cancer, Junta Provincial de Jaen (AECC) [PRDJA19001BLAY]
  7. Ministerio de Ciencia, Innovacion y Universidades [FPU19/04450]
  8. Junta de Andalucia, Consejeria de Salud y Familias [RH-0139-2020]
  9. Junta de Andalucia, Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades [DOC_01686]

向作者/读者索取更多资源

Breast cancer is the most common type of malignancy among women worldwide, but clinical response to immunotherapy is often below expectations due to immune escape mechanisms. Nanomedicine presents an opportunity to enhance the efficacy of cancer immunotherapy and overcome tumor immune escape.
Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据